$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

$eypt Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000119312518323795 Filed on November 09, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q2
Revenue	$2.442M	$486.0K	$715.0K
YoY Change	161.74%	26.23%	2.0%
Cost Of Revenue			$0.00
YoY Change
Gross Profit			$715.0K
YoY Change
Gross Profit Margin			100.0%
Selling, General & Admin	$9.270M	$7.807M	$5.732M
YoY Change	275.3%	203.54%	118.78%
% of Gross Profit			801.68%
Research & Development	$4.180M	$6.233M	$4.765M
YoY Change	-2.08%	63.21%	13.18%
% of Gross Profit			666.43%
Depreciation & Amortization	$670.0K	$43.00K	$650.0K
YoY Change	191.3%	10.26%	209.52%
% of Gross Profit			90.91%
Operating Expenses	$13.45M	$14.04M	$10.50M
YoY Change	99.53%	119.68%	53.46%
Operating Profit	-$11.01M	-$13.55M	-$9.782M
YoY Change	89.48%	125.67%	59.42%
Interest Expense	-$590.0K	$815.0K	$720.0K
YoY Change	-2066.67%		3500.0%
% of Operating Profit
Other Income/Expense, Net		-$19.57M	-$24.65M
YoY Change		-85195.65%
Pretax Income	-$11.59M	-$33.13M	-$34.43M
YoY Change	100.52%	454.01%	462.58%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.59M	-$33.13M	-$34.43M
YoY Change	100.52%	453.67%	462.92%
Net Earnings / Revenue	-474.77%	-6816.05%	-4815.1%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.010M	-$4.406M	-$6.215M
COMMON SHARES
Basic Shares Outstanding	94.86M shares	74.51M shares	54.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.30M	$55.80M	$38.80M
YoY Change	251.16%	372.88%	129.59%
Cash & Equivalents	$45.26M	$55.76M	$38.78M
Short-Term Investments
Other Short-Term Assets	$1.400M	$1.400M	$800.0K
YoY Change	180.0%	250.0%	33.33%
Inventory	$279.0K
Prepaid Expenses
Receivables	$600.0K	$500.0K	$400.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$47.60M	$57.64M	$39.91M
YoY Change	248.85%	359.41%	124.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$288.0K	$320.0K	$253.0K
YoY Change	-1.71%	-5.04%	-19.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	-33.33%	-33.33%	-33.33%
Total Long-Term Assets	$30.57M	$31.21M	$31.76M
YoY Change	5437.5%	3901.67%	3289.65%
TOTAL ASSETS
Total Short-Term Assets	$47.60M	$57.64M	$39.91M
Total Long-Term Assets	$30.57M	$31.21M	$31.76M
Total Assets	$78.17M	$88.86M	$71.67M
YoY Change	450.6%	566.73%	283.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.640M	$4.075M	$2.940M
YoY Change	78.02%	132.06%	189.37%
Accrued Expenses	$3.789M	$3.343M	$3.723M
YoY Change	67.51%	33.03%	-11.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.46M	$22.42M	$21.66M
YoY Change	404.92%	423.91%	309.51%
LONG-TERM LIABILITIES
Long-Term Debt	$17.62M	$17.46M	$17.31M
YoY Change
Other Long-Term Liabilities	$1.455M	$1.269M	$1.231M
YoY Change			2313.73%
Total Long-Term Liabilities	$19.08M	$18.73M	$18.54M
YoY Change			36252.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.46M	$22.42M	$21.66M
Total Long-Term Liabilities	$19.08M	$18.73M	$18.54M
Total Liabilities	$40.54M	$41.15M	$59.98M
YoY Change	844.43%	851.23%	1023.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$408.5M	-$396.9M	-$364.0M
YoY Change	26.63%	25.28%	17.11%
Common Stock	$445.3M	$443.8M	$374.8M
YoY Change	34.26%	36.56%	15.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.63M	$47.71M	$11.69M
YoY Change
Total Liabilities & Shareholders Equity	$78.17M	$88.86M	$71.67M
YoY Change	450.6%	566.73%	283.73%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	-$11.59M	-$33.13M	-$34.43M
YoY Change	100.52%	453.67%	462.92%
Depreciation, Depletion And Amortization	$670.0K	$43.00K	$650.0K
YoY Change	191.3%	10.26%	209.52%
Cash From Operating Activities	-$10.82M	-$11.77M	-$6.080M
YoY Change	114.68%	97.15%	36.63%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$109.0K	-$50.00K
YoY Change		70.31%	-61.54%
Acquisitions
YoY Change
Other Investing Activities	$0.00		-$1.710M
YoY Change			-168.4%
Cash From Investing Activities	-$20.00K	-$109.0K	-$1.750M
YoY Change		70.31%	-173.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$28.90M
YoY Change		2901.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	340.0K	28.86M	30.26M
YoY Change	-94.41%	2897.2%	396.07%
NET CHANGE
Cash From Operating Activities	-10.82M	-11.77M	-6.080M
Cash From Investing Activities	-20.00K	-109.0K	-1.750M
Cash From Financing Activities	340.0K	28.86M	30.26M
Net Change In Cash	-10.50M	16.99M	22.43M
YoY Change	-1109.62%	-435.4%	456.58%
FREE CASH FLOW
Cash From Operating Activities	-$10.82M	-$11.77M	-$6.080M
Capital Expenditures	-$20.00K	$109.0K	-$50.00K
Free Cash Flow	-$10.80M	-$11.88M	-$6.030M
YoY Change	114.29%	96.87%	39.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	94855705	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.50
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17048000
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	623605	shares
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35246000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	35610000
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	13336000
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3723000
CY2018Q2	us-gaap	Assets Current AssetsCurrent	39909000
CY2018Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	353000
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	926000
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	374766000
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2940000
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	838000
CY2018Q2	us-gaap	Assets Assets	71670000
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.23
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38776000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38926000
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74512048	shares
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	486812	shares
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74512048	shares
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	74000
CY2018Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	19780000
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	36964000
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	68322000
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31358000
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21663000
CY2018Q2	us-gaap	Liabilities Liabilities	59983000
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71670000
CY2018Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17309000
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	38000
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1231000
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	253000
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-129000
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-40000
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-972000
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2018Q3	us-gaap	Liabilities Liabilities	41150000
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88855000
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17463000
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	46000
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1269000
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320000
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1389000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396899000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	47705000
CY2018Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2018Q3	eypt	Accrued Interest Payable Current AccruedInterestPayableCurrent	332000
CY2018Q3	eypt	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	1039000
CY2018Q3	eypt	Accrued Development Milestone Current AccruedDevelopmentMilestoneCurrent	15000000
CY2018Q3	eypt	Employeerelated Accrued Liabilities Current EmployeerelatedAccruedLiabilitiesCurrent	1204000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	981000
CY2018	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	739000
CY2018	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	31973000
CY2018	eypt	Finite Lived Intangible Assets Foreign Currency Translation Of Accumulated Amortization FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization	737000
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	681000
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6898655	shares
CY2017Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	681000
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	182000
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5065000
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5979000
CY2017Q3	us-gaap	Depreciation Depreciation	39000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2017Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000
CY2017Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2572000
CY2018Q3	us-gaap	Assets Current AssetsCurrent	57642000
CY2018Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	489000
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	722000
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	443671000
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	780000
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-363991000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	11687000
CY2018Q2	eypt	Accrued Interest Payable Current AccruedInterestPayableCurrent	254000
CY2018Q2	eypt	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	742000
CY2018Q2	eypt	Accrued Development Milestone Current AccruedDevelopmentMilestoneCurrent	15000000
CY2018Q2	eypt	Employeerelated Accrued Liabilities Current EmployeerelatedAccruedLiabilitiesCurrent	1763000
CY2017Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.00
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11983000
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	9001000
CY2017Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3343000
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4075000
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	838000
CY2018Q3	us-gaap	Assets Assets	88855000
CY2018Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.23
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55764000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55914000
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94696272	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	486812	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94696272	shares
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	95000
CY2018Q3	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	218000
CY2018Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5200000
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37579000
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	68322000
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	30743000
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	22418000
CY2017Q3	us-gaap	Interest Expense InterestExpense	0
CY2017Q3	us-gaap	Interest Paid Net InterestPaidNet	0
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64000
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	963000
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5968000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5983000
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4000
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23000
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	6391000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6006000
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64000
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	963000
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-5983000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3819000
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	385000
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	681000
CY2017Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	963000
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39430000	shares
CY2017Q3	eypt	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-4000
CY2017Q3	eypt	Amortization Of Debt Discount AmortizationOfDebtDiscount	0
CY2017Q3	eypt	Warrants To Purchase Common Shares Expired WarrantsToPurchaseCommonSharesExpired	623605	shares
CY2017Q3	eypt	Exercise Price Of Expired Warrants ExercisePriceOfExpiredWarrants	2.50
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1397000
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10369196	shares
CY2018Q3	dei	Amendment Flag AmendmentFlag	false
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1397000
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	615000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16988000
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33126000
CY2018Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	756000
CY2018Q3	us-gaap	Interest Expense InterestExpense	815000
CY2018Q3	us-gaap	Depreciation Depreciation	43000
CY2018Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q3	dei	Document Type DocumentType	10-Q
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2018Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2018Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001314102
CY2018Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2018Q3	dei	Entity Registrant Name EntityRegistrantName	EyePoint Pharmaceuticals, Inc.
CY2018Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q3	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
CY2018Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q3	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	0
CY2018Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-18886000
CY2018Q3	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	0
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4161000
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018Q3	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	529000
CY2018Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2018Q3	us-gaap	Interest Paid Net InterestPaidNet	583000
CY2018Q3	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>1. Operations and Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (collectively, the “Company”) as of September 30, 2018 and for the three months ended September 30, 2018 and 2017 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form <font style="WHITE-SPACE: nowrap">10-K</font> for the fiscal year ended June 30, 2018 (“fiscal 2018”). In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2018, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Following U.S. Food and Drug Administration (“FDA”) approval of DEXYCU™ and YUTIQ™, the Company is targeting the direct U.S. commercial launch of YUTIQ in the first quarter of calendar 2019 and DEXYCU in the first half of calendar 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> DEXYCU™ (dexamethasone intraocular suspension) 9%, approved by the FDA in February 2018 for the treatment of post-operative inflammation, is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes the Company’s proprietary Verisome<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">®</sup> drug-delivery platform, which allows for a single injection that releases dexamethasone, a corticosteroid, over time. There are approximately four million cataract surgeries performed annually in the U.S. and the Company expects to launch DEXYCU in the U.S. in the first half of 2019 with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (“Icon”) in March 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> YUTIQ™, a <font style="WHITE-SPACE: nowrap">non-erodible</font> fluocinolone acetonide insert for the treatment of chronic <font style="WHITE-SPACE: nowrap">non-infectious</font> posterior uveitis affecting the posterior segment of the eye (chronic “NIPU”), was approved by the FDA on October 12, 2018. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis (zero order release) for approximately three years. YUTIQ is based on the Company’s proprietary Durasert™ sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years. NIPU is the third leading cause of blindness in the U.S. and is estimated to affect between 55,000 to 120,000 people. The Company expects to launch YUTIQ in the U.S. in the first quarter of calendar 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> ILUVIEN<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">®</sup> for diabetic macular edema (“DME”), the Company’s lead licensed product, was also developed from the Durasert technology platform and is sold directly in the U.S. and several European Union (“EU”) countries by Alimera Sciences, Inc. (“Alimera”). Retisert<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">®</sup>, one of the Company’s earlier generation products, was approved in 2005 by the FDA for the treatment of chronic NIPU and is sold in the U.S. by Bausch & Lomb Incorporated (“Bausch & Lomb”). The Company’s development programs are focused primarily on developing sustained release products that utilize its Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. The Company’s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has financed its operations primarily from sales of equity securities, issuance of debt and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company has a history of operating losses and, to date, has not had significant recurring cash inflows from revenue. The Company’s anticipated recurring use of cash to fund operations in combination with no probable source of additional capital raises substantial doubt about its ability to continue as a going concern for one year from the issuance of its financial statements. The Company received proceeds of $28.9 million in late September 2018 from the exercise of investor warrants (the “Second Tranche Warrants) (see Note 8) and had total cash and cash equivalents of $55.8 million at September 30, 2018. The Company believes that its cash and cash equivalents of $55.8 million at September 30, 2018, and expected proceeds from existing collaboration agreements, will enable the Company to maintain its current and planned operations (including continuation of its two Phase 3 clinical trials for YUTIQ and plans for the U.S. commercial launch of both DEXYCU and YUTIQ) into the second quarter of calendar year 2019. In order to extend the Company’s ability to fund its operations beyond then, management’s plans include obtaining additional equity financing and/or additional debt financing and/or, as applicable, reducing or deferring operating expenses. The timing and extent of the Company’s implementation of these plans is expected to depend on the amount and timing of cash receipts from existing or any future collaborations or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant revenues from its planned commercialization of DEXYCU or YUTIQ, or from its product license revenues under existing collaboration agreements or be able to obtain financing from any other sources.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Recently Adopted and Recently Issued Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted accounting pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company adopted Accounting Standards Codification (“ASC”) 606, <i>Revenue from Contracts with Customers</i>, with a date of initial application of July 1, 2018. As a result, the Company has updated its accounting policy for revenue recognition to reflect the new standard (see Note 2). The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company’s services and will provide financial statement readers with enhanced disclosures. The Company applied ASC 606 using the modified retrospective method. The cumulative effect of initially applying the new revenue standard resulted in a $218,000 reduction to the opening balance of accumulated deficit at July 1, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In February 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No. 2016-02,</font> <i>Leases</i>. The new standard establishes a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Based on the change in the Company’s fiscal year (see Note 14), ASU <font style="WHITE-SPACE: nowrap">2016-02</font> will become effective on January 1, 2019. A modified retrospective transition approach is required for lessee capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In June 2018, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2018-07,</font> <i>Improvements to Nonemployee Share-Based Payment Accounting</i>. The standard aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but not before an entity adopts the new revenue guidance. ASU <font style="WHITE-SPACE: nowrap">2018-07,</font> which was early adopted on July 1, 2018, did not have a significant impact on the Company’s financial statements.</p> </div>
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-109000
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28863000
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11766000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-33126000
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	129000
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	14040000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13554000
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109000
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2018Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	28863000
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-33126000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6233000
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	486000
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1397000
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3646000
CY2018Q3	dei	Trading Symbol TradingSymbol	EYPT
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75170000	shares
CY2018Q3	eypt	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	28863000
CY2018Q3	eypt	Finite Lived Intangible Assets Foreign Currency Translation Of Accumulated Amortization FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization	0
CY2018Q3	eypt	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	38000
CY2018Q3	eypt	Amortization Of Debt Discount AmortizationOfDebtDiscount	154000
CY2018Q3	eypt	Warrants To Purchase Common Shares Expired WarrantsToPurchaseCommonSharesExpired	0	shares
CY2018Q3	eypt	Exercise Price Of Expired Warrants ExercisePriceOfExpiredWarrants	0.00
CY2018Q3	eypt	Stock Issued During Period Shares Settlement Of Derivative Liability To Adjustment To Additional Paid In Capital StockIssuedDuringPeriodSharesSettlementOfDerivativeLiabilityToAdjustmentToAdditionalPaidInCapital	0	shares
CY2018Q3	eypt	Stock Issued During Period Value Settlement Of Derivative Liability To Adjustment To Additional Paid In Capital StockIssuedDuringPeriodValueSettlementOfDerivativeLiabilityToAdjustmentToAdditionalPaidInCapital	38666000

Files In Submission

Name	View Source	Status
0001193125-18-323795-index-headers.html	Edgar Link	pending
0001193125-18-323795-index.html	Edgar Link	pending
0001193125-18-323795.txt	Edgar Link	pending
0001193125-18-323795-xbrl.zip	Edgar Link	pending
d635570d10q.htm	Edgar Link	pending
d635570dex101.htm	Edgar Link	pending
d635570dex102.htm	Edgar Link	pending
d635570dex103.htm	Edgar Link	pending
d635570dex104.htm	Edgar Link	pending
d635570dex105.htm	Edgar Link	pending
d635570dex311.htm	Edgar Link	pending
d635570dex312.htm	Edgar Link	pending
d635570dex321.htm	Edgar Link	pending
d635570dex322.htm	Edgar Link	pending
eypt-20180930.xml	Edgar Link	completed
eypt-20180930.xsd	Edgar Link	pending
eypt-20180930_cal.xml	Edgar Link	unprocessable
eypt-20180930_def.xml	Edgar Link	unprocessable
eypt-20180930_lab.xml	Edgar Link	unprocessable
eypt-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

2018 Q4 Form 10-Q Financial Statement

#000119312518323795 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT EyePoint Pharmaceuticals, Inc. Stock $eypt

2018 Q4 Form 10-Q Financial Statement

#000119312518323795 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt